Johnson & Johnson (JNJ) Net Cash Flow Growth (1y) (2010 - 2026)
Powered by 
Analysis
Johnson & Johnson (JNJ) Net Cash Flow Growth (1y) (2010 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 650.65 Bn | 629.89 Bn | 17.26 Bn | 93.66% |
| 2 | AbbVie | 466.34 Bn | 459.82 Bn | 12.70 Bn | -323.06% |
| 3 | Merck | 362.11 Bn | 355.02 Bn | 12.21 Bn | 248.11% |
| 4 | Novartis Ag | 267.81 Bn | 260.52 Bn | 11.24 Bn | 195.58% |
| 5 | Pfizer | 157.31 Bn | 145.91 Bn | 10.94 Bn | -517.34% |
| 6 | Bristol Myers Squibb | 128.75 Bn | 117.69 Bn | 9.25 Bn | -152.92% |
| 7 | Sanofi | 51.80 Bn | 44.84 Bn | 10.79 Bn | -88.52% |
| 8 | Revolution Medicines | 40.91 Bn | 40.91 Bn | - | - |
| 9 | BeOne Medicines | 39.65 Bn | 34.55 Bn | 1.53 Bn | 75.60% |
| 10 | Incyte | 25.18 Bn | 20.65 Bn | 1.57 Bn | 3,465.10% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 28, 2026 | 93.66% |
| Mar 29, 2026 | -85.99% |
| Dec 28, 2025 | -66.34% |
| Sep 28, 2025 | 94.02% |
| Jun 29, 2025 | -3,831.57% |
| Mar 30, 2025 | 282.43% |
| Dec 29, 2024 | 115.50% |
| Sep 29, 2024 | -289.82% |
| Jun 30, 2024 | 90.87% |
| Mar 31, 2024 | -70.58% |
| Dec 31, 2023 | 152.90% |
| Apr 2, 2023 | 414.60% |
| Apr 3, 2022 | -226.86% |
| Oct 3, 2021 | -56.65% |
| Jul 4, 2021 | 136.50% |
| Apr 4, 2021 | 19.64% |
| Jan 3, 2021 | -629.94% |
| Sep 27, 2020 | 290.15% |
| Jun 28, 2020 | -1,083.69% |
| Mar 29, 2020 | 54.63% |